The Status of Metastatic Breast Cancer Management

2009 ◽  
Vol 13 (0) ◽  
pp. 2-3
Author(s):  
Suzanne M. Mahon
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cancer Management ◽  
The Status ◽  
Breast Cancer Management

PP-8-34 Metastatic breast cancer management in France

1996 ◽  
Vol 32 ◽  
pp. 55
Author(s):  
R. Launois ◽  
J. Reboul-Marty ◽  
B. Henry ◽  
P. Aussage ◽  
M.L. Abella ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cancer Management ◽  
Breast Cancer Management

Recent Advances in the Systemic Management of Metastatic Breast Cancer

2002 ◽  
Vol 15 (1) ◽  
pp. 52-61 ◽  
Author(s):  
Laura Boehnke Michaud ◽  
Kellie L. Jones
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
The United States ◽  
Similar Efficacy ◽  
Synergistic Activity ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Chemotherapy Agents ◽  
The Way

Although improvements in breast cancer management have been made, many women are diagnosed with metastatic breast cancer, an incurable stage of the disease. Several new therapies have become available over the past years that have changed the way we manage metastatic breast cancer. The new aromatase inhibitors, anastrozole, letrozole, and exemestane, are potent agents in this fight. Anastrozole and letrozole have been shown to produce superior efficacy and tolerability compared with tamoxifen as first-line endocrine therapy for metastatic breast cancer. Exemestane is being compared with tamoxifen in a similar manner, but results are pending. Trastuzumab is a monoclonal antibody directed against the HER2 oncogene with intrinsic antitumor activity and synergistic activity with traditional chemotherapy. Newer combinations with trastuzumab are also changing the way we administer other chemotherapy agents in patients who overexpress this oncogene. Traditional chemotherapy has also changed over the recent past and now includes an oral agent, capecitabine, for the treatment of metastatic breast cancer. Epirubicin, an anthracycline new to the United States, appears to have similar efficacy and toxicity to doxorubicin, with dosing issues being quite important. With all of these new agents within our grasp, there is hope for all patients with metastatic breast cancer.

Review of Clinical Studies of CA 27.29 in Breast Cancer Management

1999 ◽  
Vol 14 (1) ◽  
pp. 36-39 ◽  
Author(s):  
R.A. Beveridge
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Critical Review ◽  
Early Stage ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Review Of The Literature ◽  
Cancer Management ◽  
Breast Cancer Management

A critical review of CA 27.29 and CA 15-3 is performed in this paper. A review of the literature is undertaken. A review of the FDA submissions for 27.29 for both early stage and monitoring metastatic breast cancer patients is reviewed.

scholarly journals Use of Liposomal Doxorubicin for Metastatic Breast Cancer Management Across Europe: Results of Eos (European Observatory & Survey)

2014 ◽  
Vol 25 ◽  
pp. iv130
Author(s):  
V. Lorusso ◽  
A. Śmiałowska-Janiszewska ◽  
K. Krzemieniecki ◽  
S. Antolín Novoa ◽  
F. Mefti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liposomal Doxorubicin ◽  
Metastatic Breast ◽  
Cancer Management ◽  
Breast Cancer Management

5056 POSTER Analysis of Metastatic Breast Cancer Management Across Europe -the EOS Study (European Observatory & Survey)

2011 ◽  
Vol 47 ◽  
pp. S347
Author(s):  
S. Antolin-Novoa ◽  
G.G. Steger ◽  
K. Krzemieniecki ◽  
E. Achille ◽  
G. Carteni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cancer Management ◽  
Breast Cancer Management

scholarly journals The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner

2021 ◽  
Vol 12 (2) ◽  
Author(s):  
Kirollos Hanna, PharmD, BCPS, BCOP ◽  
Kelley Mayden, MSN, FNP, AOCNP
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Death Rate ◽  
Metastatic Breast ◽  
The United States ◽  
Cancer Society ◽  
Common Cause ◽  
Advanced Practitioner ◽  
The Status

Breast cancer is the most frequently diagnosed cancer in the United States and ranks second as the most common cause of cancer-related death among women (Siegel et al., 2020). According to American Cancer Society (ACS) estimates, approximately 276,480 new cases of breast cancer would have been diagnosed in 2020, and greater than 42,000 deaths would be attributed to breast cancer (ACS, 2020). Although only 7% of all cancer-related deaths are from breast cancer every year, it is the leading cause of death among women between the ages of 40 and 49 years (Siegel et al., 2020). The death rate associated with breast cancer, however, has decreased by 1.3% annually from 2013 to 2017.

Sign in / Sign up

Export Citation Format

Share Document